Prevention of vaginal atrophy after treatment for tumors of the female reproductive system
https://doi.org/10.17650/1994-4098-2019-15-4-73-78
Abstract
This article discusses the problems of rational pharmacotherapy in women with vulvovaginal atrophy developed after gynecological operations or during combination treatment for tumors of the female reproductive system. The range of adverse effects makes long-term treatment of these patients necessary not only to relieve the symptoms, but also to prevent possible problems, such as sexual dysfunction, postcoital bleeding, and recurrent urinary tract infections. Considering the pathogenesis of vulvovaginal atrophy associated with many unpleasant symptoms, such as dryness, burning, and dyspareunia resultedfrom low levels of estrogen, we have provided a rationale for topical application of Flamen® gel with subsequent restoration of vaginal pH. Effective relief of pain syndrome, which usually manifested itself with burning, itching, swelling, and hyperemia of the vaginal vestibule and perineal tissues, ensured maximum compliance during treatment and allowed the achievement of not only clinical, but also pathogenetic effect.
About the Author
A. G. Kedrova
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
28 Orekhovyy Boulevard, Moscow 115682
Competing Interests: no conflict of interest
References
1. Tan O., Bradshaw K., Carr B.R. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: An up-to-date review. Menopause 2012;19:109-17. DOI: 10.1097/gme.0b013e31821f92df.
2. Simon J.A., Goldstein I., Kim N.N. et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause 2018;25:837-47. DOI: 10.1097/GME.0000000000001138.
3. Jakesz R., Jonat W., Gnant M. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455—62. DOI: 10.1016/S0140-6736(05)67059-6.
4. Situation with cancer care in Russia in 2018. Ed. by A.D. Kaprin, VV Starinskiy, G.V. Petrova. Moscow: P. Herzen Moscow Oncology Research Institute — a branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 2019. 236 p. (In Russ.).
5. Kokot-Kierepa M., Bartuzi A., Kulik-Rechbergber B., Rechberger T. Local estrogen therapy-clinical implications-2012 update. Ginekol Pol 2012;83:772-7.
6. The North American Menopause Society Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902.
7. Stika C.S. Atrophic vaginitis. Dermatol Ther 2010;23:514-22. DOI: 10.1111/j.1529-8019.2010.01354.x.
8. Loibl S., Lintermans A., Dieudonne A.S., Neven P. Management of menopausal symptoms in breast cancer patients. Maturitas 2011;68:148-54. DOI: 10.1016/j.maturitas.2010.11.013.
9. Lester J.L., Bernhard L.A. Urogenital atrophy in breast cancer survivors. Oncol Nurs Forum 2009;36:693-8. DOI: 10.1188/09.ONF.693-698.
10. Chin S.N., Trinkaus M., Simmons C. et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 2009;9:109-17. DOI: 10.3816/CBC.2009.n.020.
11. Nappi R.E., Cucinella L., Martella S. et al. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). Maturitas 2016;94:87-91. DOI: 10.1016/j.maturitas.2016.09.013.
12. Palma F., Xholli A., Cagnacci A., as the Writing Group of the AGATA Study. The most bothersome symptom of vaginal atrophy: evidence from the observational AGATA study. Maturitas 2018;108:18-23. DOI: 10.1016/j.maturitas.2017.11.007.
13. Traish A.M., Vignozzi L., Simon J.A. et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev 2018;6:558-71. DOI: 10.1016/j.sxmr.2018.03.005.
14. Nappi R.E. New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric 2007;10(Suppl 2):105-8. DOI: 10.1080/13697130701599876.
15. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health 2010;19:425-32. DOI: 10.1089/jwh.2009.1384.
16. Trinkaus M., Chin S., Wolfman W et al. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222-31. DOI: 10.1634/theoncologist.2007-0234.
17. Moegele M., Buchholz S., Seitz S., Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 2012;285:1397-402. DOI: 10.1007/s00404-011-2181-6.
18. Pruthi S., Simon J.A., Early A.P. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 2011;17:403-8. DOI: 10.1111/j.1524-4741.2011.01089.x.
19. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A. et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-73.
20. Nappi R.E., Biglia N., Cagnacci A. et al. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol 2016;32:602-6. DOI: 10.1080/09513590.2016.1183627.
Review
For citations:
Kedrova A.G. Prevention of vaginal atrophy after treatment for tumors of the female reproductive system. Tumors of female reproductive system. 2019;15(4):73-78. (In Russ.) https://doi.org/10.17650/1994-4098-2019-15-4-73-78
Views:
1447
Email this article 